HOME >> MEDICINE >> NEWS
Targeting cell fusion as possible way to repair organs, deliver cancer vaccines

of cancer -- can be killed. "Our biofusion research brings a new level of control to the system so the right fusion matches are made to serve therapeutic ends," says Dr. Russell. "It offers a biotechnology platform that provides a way to choose and direct the agents of fusion by getting tumor cells to fuse with dendritic cells -- one cell type in the immune system. The result is biofusion that prompts the immune system to attack the tumor.

"This is important because the exploitation of cell fusion, whether for killing cancer cells, repairing damaged tissues or stimulating the immune system, depends on making sure that it is accurately targeted," he says.

Potential Applications

The ability to fuse tumor cells to treat cancers is one application the Mayo Clinic cancer research team envisions for their biofusion platform.

Another possible application involves cancer vaccines that prevent cancer from progressing or developing. Current vaccine approaches involve taking dendritic cells from cancer patients, feeding the dendritic cells tumor antigens, and then reintroducing the dendritic cells into the patient's body and relying on the body's natural process of "instruction" to help the body create cells that attack cancer. In this natural system, dendritic cells present antigens to other immune cells in a way that effectively "teaches" them what they are to attack.

Dr. Russell believes the biofusion technology would be a better way of "feeding" the dendritic cells the information they need to "learn" what they are to attack.

"Biofusion would involve putting genes in the dendritic cells inside the body that will cause them to fuse directly into tumors at multiple sites in the patient," he says. He notes that Mayo Clinic cancer research colleague Richard Vile, Ph.D., last year successfully fused tumor and dendritic cells to create a hybrid of the two -- but it was not targeted. "So this is not blue-sky stuf
'"/>

Contact: Mary Lawson
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
17-Feb-2004


Page: 1 2 3

Related medicine news :

1. Targeting mutant B-Raf protein reduces melanoma development
2. Jefferson and Molecular Targeting Technologies, Inc. scientists create vaccine for wildlife rabies
3. Targeting bone metastasis and hypercalcemia
4. Effective Obesity Treatment Likely To Require Targeting Of Multiple Weight Control Systems
5. Diffusion-weighted MRI can diagnose mad cow-related disease in humans before symptoms show
6. Article highlights confusion about Homeland Security safety symbols
7. Information fusion research simulates disasters to manage emergency response
8. NHLBI stops sickle cell anemia transfusion study
9. Ongoing transfusions needed to avoid strokes in children with sickle cell disease
10. Blood transfusion poses CJD risk
11. Mayo researchers observe genetic fusion of human, animal cells -may help explain origin of AIDS

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
Cached News: